CIS-Asia 2026 Shanghai | The 19th BestMedia International Conference & Exhibition on Chemical & Pharmaceutical Sciences
CIS-Asia 2026 Shanghai | The 19th International Conference and Exhibition on Chemical Pharmaceuticals
Conference Information
CIS-Asia 2026 Shanghai
Conference Framework
CIS-Asia 2026 Shanghai
Conference Framework
CIS-Asia 2026 Shanghai
Real-name Verification, Limited Seats Available
Please register by locking in the date.
Limited Seats · Register Now
Conference Guests
CIS-Asia 2026 Shanghai
Conference Agenda
CIS-Asia 2026 Shanghai
AM / April 23Sun.
Yu Xiong, Honorary Chairman, Pharmaceutical Engineering Professional Committee of the Chinese Pharmaceutical Association
Yu Xuanqiang, Director of the Product Quality Evaluation Department,FDA
▶10:30 Tea Break
▶ 11:00 Green Intelligent Manufacturing of Chiral Drugs
Zhang Wanbin, Academician of the Chinese Academy of Sciences, Chair Professor at Shanghai Jiao Tong University
▶ 11:30 New Global Regulatory Trends and Compliance Risk Control for Innovative Drugs Going Global
Sun He, Deputy Director of Hainan International Medical Center, Shanghai Jiao Tong University School of Medicine
▶12:00 Lunch
April 23–24
Conference Planning
Zhang RuPeople,Chief Scientific Officer, Global Health Drug Discovery Institute
✔ Topic 1 - AI-Driven New Drug Discovery and Design
✔ Theme 2: Conquering "Undruggable" Targets: Technological Breakthroughs in Frontier Modalities
✔ Topic 3 – From Bench to Bedside: Translational Science and Dosing Decisions
Bai Chang,Co-CEO & CSO, Yuanli Life Sciences
▶ 14:10 PROTACBreakthroughs in Oral Drug Delivery: Molecular Design Strategies, Preclinical Development Challenges, and Recent Research Advances
Wu Du, Senior Vice President of Medicinal Chemistry, Haichuang Pharmaceutical
▶ 14:50 HumanAIThe New Art of Collaborative Pharmaceutical Innovation
Guo Jinjiang, Head of the AI and Data Science Department, Global Health Drug Discovery Institute
▶ 15:30 Tea Break
▶ 16:00 AIApplications and Practices of Technology in Drug Discovery
Han Lianyi,AIDDHead of Drug R&D, Jiangsu Hengrui Pharmaceuticals
▶ 16:40 Nanoconjugate DrugsDelivery Process and Clinical Translation
Zhang Fuyao, Chairman/CEO, Biling Bio
▶ 17:20 Roundtable Discussion: How to View the Application of Artificial Intelligence in Various Stages of New Drug Development?
Bian Feng, Executive Director/Head of the China Integrated Science Team for Global Drug R&D,BMS
Bai Chang,Co-CEO & CSO, Yuanli Life Sciences
Du Wu, Senior Vice President of Medicinal Chemistry, Haichuang Pharmaceutical
Han Lianyi,AIDDHead of Drug R&D, Jiangsu Hengrui Pharmaceuticals
Zhang Fuyao, Chairman/CEO, BiLink Bio
Gu Manqin, General Manager, Gude Consulting Co., Ltd.
▶ 18:00 Day 1 of the Conference Concludes
▶ 09:00 How to ApplyAI/MLAccelerating the Design and Optimization of Novel Drugs
Chen Bingjun, Director of Modeling and Translational Biology, FormerGSK
▶ 09:40 OralKRASDevelopment and Latest Advances in Inhibitors
Li Yingfu, Founder, Chengdu Haibowei Pharmaceutical
▶ 10:20 Tea Break
▶ 10:50 Breaking Through the “Undruggable” Frontier—PPISmall-Molecule Modulators
Cheng Dai, Senior Vice President, Bio-Thera Solutions
▶ 11:30 Optimizationlinker payloadAlleviateADCOff-target toxicity
Gu Manqin, General Manager, Gude Consulting Co., Ltd.
▶ 12:10 Lunch
▶ 13:30 Innovative Pathways to Expand the Therapeutic Window
He Yun, Co-Director of the Translational Innovation Center, Shenzhen Bay Laboratory
▶ 14:10 R&D and Case Sharing of Oral Small-Molecule GLP-1 Receptor Agonists
Lin Jian, CBO, MindRank AI
▶ 14:50 Tea Break
▶ 15:20 PROTACsDevelopment and Validation of Selective Chemical Tools
Liu Huaqing, Executive Director, Viatrylon
▶ 16:00 Breaking Through the R&D Pathway and Industrialization Challenges of “Undruggable” Targets
▶ 16:40 Conference Concluded
April 23–24
Topic Direction
✔ Topic 2: Key Points on API Quality – Starting Materials, Impurities, Crystal Forms, and CMC Submission Essentials
✔ Topic 3 – Industrial Upgrading and Compliance of Active Pharmaceutical Ingredients
▶ 13:30 AIData-Driven Synthetic Route Design and Retrosynthetic Analysis: Accelerating the Synthesis Efficiency of Drug Molecules
Tu Shikui, Associate Professor, Shanghai Jiao Tong University
▶14:10 CMCAI Vertical Large Language Model with Full-Chain R&D
Jin Chuanfei, Deputy General Manager, HEC Pharm
▶14:50 Xtalgazer®:New Automated and Intelligent Solutions for Pharmaceutical Crystallization Research
Zhang Yizu, Senior Scientist in Solid-State Computing, XtalPi
▶15:30 Tea Break
▶16:00 From Lab to Factory:AIChallenges and Solutions in Process Scale-Up Driven by
Liang Xing, Senior Director&CMCHead, Haiyingxi Intelligence
▶16:40 AIAutomated Experimental Platform: Closed-Loop Synthetic Process Development
Xia Ning,CEO , Wuhan Zhihua Technology
▶17:20 Roundtable Discussion: Challenges and Prospects of Technological Breakthroughs in Active Pharmaceutical Ingredients (APIs) and Industrial Upgrading(AI, synthetic biology, continuous flow, green intelligent manufacturing, etc.)
Zhu Wei, Deputy General Manager, Huahai Pharmaceutical
Tu Shikui, Associate Professor, Shanghai Jiao Tong University
Jin Chuanfei, Deputy General Manager, HEC Pharm
Liang Xing, Senior Director&CMCHead, Shanghai Insilico Medicine
Xia Ning,CEO , Wuhan Zhihua Technology
▶18:00 Day 1 of the Conference Concludes
▶09:00 Development and Regulatory Submission of Analytical Methods for Impurities in Active Pharmaceutical Ingredients (APIs) of Small-Molecule Chemical Drugs Across Different R&D Stages
Tang Qinglin, Chief Technology Officer, Fukang Pharmaceutical
▶09:40 FromINDtoNDACommon in Active Pharmaceutical Ingredient (API) DevelopmentCMCQuestion
Li Wenjie,CMCVice President, Shanghai Jiyu Pharma
▶10:20 Tea Break
10:50 Active Pharmaceutical Ingredient (API)Genotoxic ImpuritiesControl Strategies and Risk Assessment
Xu Su, Director of Analytics, Novartis Pharmaceuticals
▶11:30 Topic Confirmation in Progress
Ma Jianguo, Senior Vice President, WuXi Biologics
▶12:10 Lunch
▶13:30 Control of Starting Materials for Active Pharmaceutical Ingredients and Case Studies
Zheng Changsheng, Deputy General Manager, Enkang Pharmaceutical
▶14:10 Impurity Study and Control of Starting Materials and Intermediates Based on Their Impact on the Quality of Drug Substance
Wang Zhongqing, R&D Director, HEC Pharm
▶14:50 Tea Break
▶15:20 The Impact of Crystal Forms on the Development of New Small-Molecule DrugsCMCImpact and Strategies of Process and Quality Control
Xie Yangyin,CMCDeputy Director, Anrui Biopharmaceuticals
▶16:00 Key Points and Case Analysis of API Registration Inspection
Chen Anping, Head of R&D and Registration, Jiuzhitang
▶16:40 Conference Concluded
April 23-24
Conference Planning
Yihong Qiu, Founder, QPD Solution
✔ Topic 1: Rational Development and Evaluation of Pediatric Drug Formulations
✔ Topic 2 - Formulation and Process Development: Multiple-Unit Systems
✔ Topic 3 - Development of Poorly Soluble Drug Formulations and New Technologies
▶13:30 Development and Challenges of New Formulations for Pediatric Drugs
Guo Xiaodi, Former Chief Scientist and Senior Vice President of the Formulation Business Unit at Huahai Pharmaceutical
▶ 14:15 Key Points, Risk Control, and Case Studies: From Pre-Formulation Research to Successful Drug Product Development
Shi Bin, Director of Formulation, Shanghai Allist
▶ 15:00 Case Analysis of the Application of Innovative New Technologies in Formulations of Poorly Soluble and Taste-Masking Drugs
Hu Yonggang, Professor/PhD Supervisor, Pucui Supercritical
▶ 15:30 Tea Break
▶ 16:00 Common Issues in Pre-Market Formulation Research and Manufacturing
Wu Zhenping, Former Executive Vice President of Hutchison MediPharma
▶ 16:40 Poorly solublePROTACDrugThe Formulation Revolution: From Nanocrystals to Amorphous Solid Dispersions
Wang Zeren, Chairman/CSO, Yaoxin Biopharma
▶ 17:20 Roundtable Discussion: Development Opportunities and Future Trends in Pediatric Medication
Guo Xiaodi, Former Chief Scientist and Senior Vice President of the Formulation Business Unit at Huahai Pharmaceutical
Shi Bin, Director of Formulation, Shanghai Allist
Hu Yonggang, Professor/Doctoral Supervisor, Pucui Supercritical
Wu Zhenping, Former Executive Vice President of Hutchison MediPharma
Wang Zeren, Chairman/CSO, Yaoxin Biologics
▶ 18:00 Conclusion of Day 1 Conference
▶ 09:00 Small-molecule new drugsBD licensing CMC Focus on Issue Exploration
Wang Zhixuan,CMCBusiness&Director of External Partnerships, Sanofi
▶ 09:40 Key Elements and Case Studies: From Drug Development to Commercial Production
Deepak Hedge，GM & China Site Head，Cipla (Jiangsu) Pharmaceutical
▶ 10:20 Tea Break
▶ 10:50 Pellet FormulationR&D — Experimental Study on the Calculation of R&D Boundaries and Storage Structure 60min
Tang Lijuan, President, Philadelphia Laboratory, USA
▶ 12:00 Lunch
▶ 13:30 Challenges and Innovations in the Development of Orally Disintegrating Formulations (e.g.:Orally Disintegrating Tablets/Film Formulation Development Technology)
Han Jun, Professor/Dean, Institute of Biopharmaceuticals, Liaocheng University
▶ 14:10 Selection and Optimization of Pediatric Drug Dosage Forms--Rationalizing Product Design Elements
Wu Zhenghong, Professor/Ph.D. Supervisor, China Pharmaceutical University
▶ 14:50 Tea Break
▶ 15:20 Key Control Points and Case Studies in the Scale-Up of Solid Oral Dosage Forms: From Formulation Design to Process Scale-Up
Jiang Shaobo, Head of Formulation, Johnson & Johnson Pharmaceutical R&D Center, Shanghai
▶ 16:00 Roundtable Discussion: Exploring the Practice and Control of QbD Principles in Formulation Design and Process Development
Wang Zhixuan,CMCBusiness&Director of External Partnerships, Sanofi
Tang Lijuan, President, Philadelphia Laboratory, USA
Han Jun, Professor/Dean, Institute of Biopharmaceuticals, Liaocheng University
Wu Zhenghong, Professor/Ph.D. Supervisor, China Pharmaceutical University
Jiang Shaobo, Head of Formulation, Johnson & Johnson Pharmaceutical R&D Center (Shanghai)
▶ 16:40 Conference Concluded
April 23–24
Conference Planning
Xi Fengde,Former Vice President, USP-China; CMC Consultant
✔Topic 1 - Pharmacopoeia Interpretation and Compliance Strategies
✔Topic 2: Analysis of Complex Formulations and Technological Innovation
✔Topic 3 - Practice and Optimization of Analytical Methods
▶ 13:30 Control Strategies for Elemental Impurities and Genotoxic Impurities Under the New Pharmacopoeia Regulations
Yang Yongjian,Former Chief Expert of the Shanghai Institute for Food and Drug Control
▶14:30 Compliance Strategies for Pharmacopoeial Analytical Method Changes and Enhancement of Laboratory Efficiency
Chen Hong, Executive Dean of the Central Research Institute, Dean of the Hangzhou Research Institute, Huahai Pharmaceutical
▶15:30 Tea Break
▶16:00 Development of Analytical Methods for Complex and Novel Formulations
Yan Zimeng, Senior Consultant Expert
▶17:00 Roundtable Discussion:Discussion on Lessons Learned and Successful Recommendations for Method Transfer and Validation
Yang Yongjian,Former Chief Expert, Shanghai Institute for Food and Drug Control
Chen Hong, Executive Dean of the Central Research Institute, Dean of the Hangzhou Research Institute, Huahai Pharmaceutical
Yan Zimeng, Senior Consultant and Expert
▶17:40 Day 1 of the Conference Concludes
▶09:00 Q3EImplementation of Guidelines for Extractables and Leachables
Xi Fengde, formerUSP-ChinaVice President,CMCConsultant
▶10:00 Quality Management Strategy for the Full Lifecycle of Analytical Methods
Zhou Zhenhua, Senior Vice President, Pharmaron
▶10:40 Tea Break
▶10:50 Accelerating Predictive Stability—Application and Practice of Stability Modeling under the New ICH Q1 Guideline
Wang Likun, General Manager, Nanjing Haiwei Pharmaceutical
▶11:30Analysis, Quality Research Strategies, and Case Studies for New Drug Clinical Trial Applications
Wang Yilun,CMCSenior Director, Aimei Medical
▶12:10 Lunch
▶13:30 ICH Q2(R2)Analytical Method Validation Below
Xu Jufang, Director of Analysis, Changfeng Pharmaceutical
▶14:10 Application of Statistics in Analytical Method Validation
Zeng Wenliang,CMCDeputy Director, Dizal Pharma
▶14:50 Tea Break
▶15:20 Key Considerations for the Registration Process and Quality Research of Imported Products
Ting Zhao, Director of Analytics, Nianyan Pharmaceutical
▶16:00 Case Analysis of Responses to Requests for Supplementary Information and Communication Issues in Quality Research for Drug Development
Ye Haiying, Deputy Director of the Institute of Pharmaceutical Research, Chia Tai Tianqing Pharmaceutical
▶16:40 Conference Concluded
April 23-24
Topic Direction
✔Topic 1: R&D and Industrialization Breakthroughs in Complex Injectable Technologies
✔Topic 2: Process Optimization and Quality Control of Complex Injectables
▶13:30 Development of Novel Formulations for Improved Injectable Drugs and Application of New Technologies
Chen Tao, President, Medixin Biotech
▶ 14:10 Preclinical and Clinical Development of HNC364: A Long-Acting Sustained-Release Injectable Prodrug of Rasagiline
Zhang Jiancun, Chairman/General Manager, Guangzhou Hengnuokang Pharmaceutical
▶ 15:00 West Pharmaceutical Services' Value Proposition for Coated Rubber Stoppers
Zhu Wenjing, Scientific Affairs&Technical Support Specialist, West Pharmaceutical Packaging
▶ 15:30 Tea Break
▶ 16:00 Amphiphilic CopolymersPLA-PEGApplications in Drug Delivery
Zhang Xichen, Founder, Hangzhou Shixi Pharmaceutical
▶ 16:40 Challenges in Liposome Manufacturing Process Development and Solutions: Sharing of Experience
Zhou Jinpeng, R&D Director, Zhejiang Zhida Pharmaceutical
▶ 17:20 Roundtable Discussion: Product Innovation, R&D Strategies, and Challenges in Complex Injectables
Chen Tao, President, Medixin Biotech
Zhang Jiancun, Chairman/General Manager, Guangzhou Hengnuokang Pharmaceutical
Zhang Xichen, Founder, Hangzhou Shixi Pharmaceutical
Zhou Jinpeng, R&D Director, Zhejiang Zhida Pharmaceutical
▶ 18:00 Day 1 of the Conference Concludes
▶ 09:00 Experimental Design and Development of Improved Injections Based on Hot-Melt Extrusion Technology
Qu Wei,CTO, Shenzhen Shengkang Pharmaceutical
▶ 09:40 Research on Novel Long-Acting Modified Formulations
Zhang Jiantao, Researcher/Ph.D. Supervisor, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences
▶ 10:20 Tea Break
▶ 10:50 Advances in USP Standards for Excipients in Complex Injectables and Solutions
Cao Hongxin, Senior Director of Strategic Account Development, Greater China, United States Pharmacopeial Convention
▶ 11:30 Simplification and Streamlining of Long-Acting Sustained-Release Injectables: Farewell to Cumbersome Processes, Achieving Stable Scale-Up
Jin Tuo, Chief Delivery Scientist, Shanghai Jiao Tong University Translational Medicine Center
▶ 12:10 Lunch
Afternoon of April 24
✔ Topic 1 - From Innovative Design to Industrialization of Improved New Drugs
▶13:30 Rediscovering Paclitaxel: Challenges and Breakthroughs in the Development of New Oral Paclitaxel Drugs
Afternoon of April 23
Conference Planning
Shao Jun,COO, Tongyi Pharma
Yang Yi, Chief Scientist, Ferring Pharmaceuticals
▶ 13:30 Peptide Functional Domain Strategies Empower the Development of Antiviral Drugs and Biomaterials
Jiang Shibo, Professor, Fudan University
▶ 14:10 Peptide-Drug ConjugatesPDCDesign and Development
Zhang Puwen, General Manager, Handing Pharmaceutical
▶ 14:50 Tea Break
▶ 15:20 Development of Multi-Target Peptides for Blood-Brain Barrier Delivery
Wang Zhuyin, Chairman, Shenzhen Taisheng Biotechnology
▶ 16:00 Development of Peptide-Conjugated Radionuclide Drugs and Case Studies
He Yantao, Vice President of R&D and Head of the Formulation Department, Zhongsheng Quanpei
▶ 16:40 Peptide Modification and Optimization Technologies
Wan Yang, Associate Professor/Ph.D. Supervisor, Jiangxi Science and Technology Normal University
▶ 17:20 Roundtable Discussion: Technological Innovations in the Peptide Sector and the Future of Industry Development
Shao Jun,COO, Tongyi Medicine
Jiang Shibo, Professor, Fudan University
Wang Zhuyin, Chairman, Shenzhen Taisheng Biotech
Zhang Puwen, General Manager, Handing Medicine
He Yantao, Vice President of R&D and Head of the Formulation Department, Zhongsheng Quanpeptide
Wan Yang, Associate Professor/Ph.D. Supervisor, Jiangxi Science and Technology Normal University
▶ 18:00 Conference Concluded
April 24
Shao Jun,COO, Tongyi Medicine
Yang Yi, Chief Scientist, Ferring Pharmaceuticals
✔ Topic 2 - Green and Efficient Peptide Synthesis and Scale-Up
✔ Topic 3 - Peptide Quality Control and Compliance
▶ 09:00Exploring New Approaches to Enhance Peptide Synthesis Efficiency and Green Chemistry
Su Xianbin, Professor, Nanjing Tech University
▶09:40 Quality Control and Regulatory Requirements for Peptide Drugs-Case Sharing
Shao Jun,COO, Tongyi Medicine
▶10:20 Tea Break
▶10:50 Global Compliance Strategy for the Impurity Profile of Peptide Drugs
Jiang Jianjun, Vice President of the Group and General Manager of the Peptide Business Unit, Nuotai Bio
▶11:30 Impurity Identification and Case Analysis of Peptide Drugs
Liu Guozhu, Chairman, Changsha Chenchen Pharmaceutical
▶12:10 Lunch
▶13:30 Long-Acting Delivery of Peptide Drugs and Case Studies
Liu Nengyin,CEO/Co-founder, United StatesHepaBio
▶14:10 Pharmacopoeial Requirements for Peptide DrugsUSP
Tie Zou, Senior Manager, Biologics, USP China
▶14:50 Tea Break
▶15:20 R&D of Peptide Powder Products Based on Novel Spray Granulation Technology
Wu Duo, Professor, Soochow University
▶16:00 MicotDesign of Novel Multi-Target Peptide Drugs,CMCDevelopment and Clinical Value
Fan Jun,CMCVice President, R&D Center, Shaanxi Microwatt
▶16:40 Conference Concluded
April 23–24
Pan Honghui, CEO, Sirnaomics
Wang Haisheng, Founder, Sihe Gene Biotech
Co-organizers
✔ Topic 2 - Oligonucleotide Delivery Technologies and Patent Layout
✔ Topic 3 - Quality Control, Analysis, and Compliance of Oligonucleotide Drugs
▶ 13:30 Current Status, Trends, and Differentiated R&D Strategies for Oligonucleotide Therapeutics
Wang Haisheng, Founder, Sihe Gene Bio
▶ 14:10 Research and Challenges in the Long-Acting Formulation of Small Nucleic Acid Drugs
Yang Xianbin, Former CSO of Sirnaomics
▶ 14:50 Small Nucleic Acid-Based Drug Discovery Technology Across Novel Modalities
Ma Xingquan, Co-President, ChemPartner
▶ 15:30 Tea Break
▶ 16:00 ForCNSNucleic Acid Drug Development for Diseases
Xu Yuhong, Chief Executive Officer and Chief Scientific Officer, Gaotian Biologics
16:40 Advantages and Clinical Applications of the Sinotech Delivery Platform
Tian Weiwei, Vice President of R&D at Sinocare Group, and concurrently General Manager of Sinopharm (Suzhou)
▶ 17:20 Roundtable Discussion: Small Nucleic AcidsCMCDevelopment andCRO，CDMOWin-Win Cooperation
Yu Jianhua, Vice President, Darui Biologics
Wang Lijuan,CSO, Shenzhen Salubris
Wang Haisheng, Founder, Sihe Gene Biology
Tian Weiwei, Vice President of R&D at Sinotech Group, also serves at Sinopharm(Suzhou)General Manager
Ma Xingquan, Co-President, ChemPartner
▶ 18:00 Conference Concluded
▶ 09:00 Antibody-Oligonucleotide Conjugates: A Promising Therapeutic Approach
Zhao Chengjiang, Co-founder, Youjia (Hangzhou) Biopharmaceuticals
▶ 09:40 Oligonucleotide Active Pharmaceutical Ingredient (API): Process, Manufacturing, and Quality Control
Li Qing, Deputy General Manager, Tianjin New Nuclear Source
▶ 10:20 Tea Break
▶ 10:50 TidesNMR Characterization of Drugs
Huiwen Deng, Pharmaceutical Market Development and Sales Manager, Bruker
▶ 11:20 Bioanalytical Methods: Technology Applications and Solutions
Wang Laixin, Senior Vice President, Chongqing Denali Pharmaceutical
▶ 12:00 Lunch
▶ 13:30 siRNAResearch Progress on Extrahepatic Drug Delivery
Han Xiaofeng, Head of the Biology Department, Suzhou Xuanjing Biotech
▶ 14:10 Patent Layout and Protection Issues for Delivery Platforms
Qi Qi, Managing Partner, Xinyuan Zhenghe (Hangzhou) Private Equity Fund
▶ 14:50 Tea Break
▶ 15:20 PioneeringASODruggability: From Traditional Design to a New Landscape
Chen Shengpei,CEO, Shenzhen Hard Nucleic Acid Biology
▶ 16:00 Progress and Prospects of Small Nucleic Acid Drug Development in Ophthalmology
Wu Junjun, Chief Scientist, Runer Biotech
▶ 16:40 Conference Concluded
Media Partners
CIS-Asia 2026 Shanghai
